The Novel Melatonin Agonist Agomelatine (S20098) Is an Antagonist at 5-Hydroxytryptamine2C Receptors, Blockade of Which Enhances the Activity of Frontocortical Dopaminergic and Adrenergic Pathways

@article{Millan2003TheNM,
  title={The Novel Melatonin Agonist Agomelatine (S20098) Is an Antagonist at 5-Hydroxytryptamine2C Receptors, Blockade of Which Enhances the Activity of Frontocortical Dopaminergic and Adrenergic Pathways},
  author={Mark J. Millan and Alain P. Gobert and Françoise Lejeune and Anne Dekeyne and Adrian Newman-Tancredi and Valérie Pasteau and Jean Michel Rivet and Didier Cussac},
  journal={Journal of Pharmacology and Experimental Therapeutics},
  year={2003},
  volume={306},
  pages={954 - 964}
}
  • M. Millan, A. Gobert, D. Cussac
  • Published 1 September 2003
  • Biology, Chemistry
  • Journal of Pharmacology and Experimental Therapeutics
Agomelatine (S20098) displayed pKi values of 6.4 and 6.2 at native (porcine) and cloned, human (h)5-hydroxytryptamine (5-HT)2C receptors, respectively. It also interacted with h5-HT2B receptors (6.6), whereas it showed low affinity at native (rat)/cloned, human 5-HT2A (<5.0/5.3) and 5-HT1A (<5.0/5.2) receptors, and negligible (<5.0) affinity for other 5-HT receptors. In antibody capture/scintillation proximity assays, agomelatine concentration dependently and competitively abolished h5-HT2C… 
View on ASPET
jpet.aspetjournals.org
495 Citations
Highly Influential Citations
42
Background Citations
201
Methods Citations
5
Results Citations
9

Figures from this paper

495 Citations

Citation Type

Citation Type

S32006, a novel 5-HT2C receptor antagonist displaying broad-based antidepressant and anxiolytic properties in rodent models
TLDR
In vitro and in vivo, the novel benzourea derivative, S32006 is a potent 5-HT2C receptor antagonist, and possesses antidepressant and anxiolytic properties in diverse rodent models.
The melatonergic agonist and clinically active antidepressant, agomelatine, is a neutral antagonist at 5-HT(2C) receptors.
TLDR
Agomelatine behaves as a neutral antagonist at constitutively active h5-HT 2C(INI)Rs and native, cortical 5-HT2CRs and is of interest to determine whether the neutral antagonist properties of agomel atine are related to its favourable clinical profile of antidepressant properties with few side-effects and no discontinuation syndrome.
The effect of agomelatine on 5HT2C receptors in humans: a clinically relevant mechanism?
TLDR
The extent to which SWS can be used as a marker of the functional status of the 5HT 2C receptor is not entirely certain, indeed alternate explanations for the lack of effect of agomelatine on SWS have been canvassed.
Differential effects of the novel antidepressant agomelatine (S 20098) versus fluoxetine on 5-HT1A receptors in the rat brain
5-Hydroxytryptamine receptors (version 2019.4) in the IUPHAR/BPS Guide to Pharmacology Database
TLDR
Unique amongst the GPCRs, RNA editing produces 5-HT2C receptor isoforms that differ in function, such as efficiency and specificity of coupling to Gq/11 and also pharmacology [40, 482].
Synthesis and Pharmacological Evaluation of a series of the Agomelatine Analogues as Melatonin MT1/MT2 Agonist and 5‐HT2C Antagonist
TLDR
A series of naphthalenic derivatives was designed and synthesized as novel analogues of agomelatine that exhibited good binding affinity at the melatonin MT1 and MT2 receptor subtypes and at the serotonin 5‐HT2C receptor subtype.
Role of melatonin, serotonin 2B, and serotonin 2C receptors in modulating the firing activity of rat dopamine neurons
TLDR
The combination of melatonin receptor activation as well as 5-HT2C receptor blockade resulted in a disinhibition of DA neurons, thus reproducing the effect of agomelatine.
Antidepressant-like activity of S 20098 (agomelatine) in the forced swimming test in rodents: involvement of melatonin and serotonin receptors.
TLDR
It is concluded that the antidepressant-like activity of S 20098 in this model most probably involves a combination of both its melatonin agonist and 5-HT(2C )receptor antagonist properties.
Investigating the Potential Role of Serotonin-2B Receptor Antagonism in the Neuronal Actions of Adjunctive Aripiprazole
TLDR
5-HT2B receptor blockade rescues an SSRI-mediated decrease in DA firing activity and increases mPFC pyramidal neuron firing and bursting activity mediated by aripiprazole and in combination with escitalopram may be, at least partly, moderated by 5- HT2B receptors expressed in this brain area.
Agomelatine-induced responses in rat aorta
TLDR
The results indicate that nitric oxide, Ca2+-activated K+ channels and also phosphodiesterase played role in agomelatine-induced relaxation.
...
...

References

SHOWING 1-10 OF 76 REFERENCES
5-HT2C receptor agonists: pharmacological characteristics and therapeutic potential.
TLDR
The results suggest that 5-HT2C receptor agonism is associated with therapeutic potential in obsessive compulsive disorder and depression.
5-HT2C receptors mediate penile erections in rats: actions of novel and selective agonists and antagonists.
5-HT 2C Receptor Agonists: Pharmacological Characteristics and Therapeutic Potential
TLDR
The results suggest that 5-HT2C receptor agonism is associated with therapeutic potential in obsessive compulsive disorder and depression.
Melatonin modulates the sensitivity of 5-hydroxytryptamine-2 receptor-mediated sleep—wakefulness regulation in the rat
Serotonin 5-HT2c agonists mimic the effect of light pulses on circadian rhythms
Melatonin agonists modulate 5-HT2A receptor-mediated neurotransmission: behavioral and biochemical studies in the rat.
TLDR
The present data support an interaction between melatonin and 5-HT2A receptors in the central nervous system and in vitro incubation of cortical slices with melatonin agonists robustly inhibited 5- HT2A receptor-mediated PI hydrolysis in a noncompetitive manner.
Differential activation of Gq/11 and Gi(3) proteins at 5-hydroxytryptamine(2C) receptors revealed by antibody capture assays: influence of receptor reserve and relationship to agonist-directed trafficking.
TLDR
H5-HT(2C) receptors couple to both Gq/11 and Gi(3) in CHO cells, and efficacy for G protein subtype activation is both ligand- and receptor reserve-dependent, as determined by a guanosine 5'-O-(3-[(35)S]GTPgammaS]thio)triphosphate binding assay.
Evidence for accelerated desensitisation of 5-HT2C receptors following combined treatment with fluoxetine and the 5-HT1A receptor antagonist, WAY 100,635, in the rat
Determination of the dose of agomelatine, a melatoninergic agonist and selective 5-HT2C antagonist, in the treatment of major depressive disorder: a placebo-controlled dose range study
TLDR
It is demonstrated that agomelatine is efficient in the treatment of major depressive disorder and that 25 mg is the target dose.
Characterization of phospholipase C activity at h5-HT2C compared with h5-HT2B receptors: influence of novel ligands upon membrane-bound levels of [3H]phosphatidylinositols
TLDR
This rapid and innovative method for determination of PLC activity permitted characterization of an extensive range of novel ligands at h5-HT2C receptors, including Ro600332, Ro600175 and BW723C86, which showed "full" efficacy at h3HPI sites and antagonist potency and binding affinity were highly correlated.
...
...